Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Attal, Michel; Lauwers‐Cancès, Valérie; Hulin, Cyrille; Leleu, Xavier; Caillot, Denis; Escoffre, Martine; Arnulf, Bertrand; Macro, Margaret; Belhadj, Karim; Garderet, Laurent; Roussel, Murielle; Payen, Catherine; Mathiot, Claire; Paul Fermand, Jean; Meuleman, Nathalie; Rollet, Sandrine; E. Maglio, Michelle; A. Zeytoonjian, Andrea; Weller, Edie; C. Munshi, Nikhil; C. Anderson, Kenneth; G. Richardson, Paul; Façon, Thierry; Avet‐Loiseau, Hervé; Harousseau, Jean‐Luc; Moreau, Philippe

doi:10.1056/nejmoa1611750

Public

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Published in New England Journal of Medicine • Apr 5, 2017

Authors:

Michel Attal

Valérie Lauwers‐Cancès

Cyrille Hulin

Abstract

BACKGROUND: High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this ...

Subject

Lenalidomide

Bortezomib

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!